# Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

> **NCT00111787** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 49 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00111787
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04-11
- **Primary completion:** 2006-11-01
- **Final completion:** 2006-11-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111787, "Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00111787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*